A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

INTRODUCTION: Combretastatin A4-phosphate, fosbretabulin tromethamine (CA4P) is a vascular disrupting agent that targets tumor vasculature. This study evaluated the safety of CA4P when combined with carboplatin, paclitaxel, and bevacizumab in chemotherapy-naïve subjects with advanced nonsquamous, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Garon, Edward B, Neidhart, Jeffrey D, Gabrail, Nashat Y, de Oliveira, Moacyr R, Balkissoon, Jai, Kabbinavar, Fairooz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138047/
https://www.ncbi.nlm.nih.gov/pubmed/27942221
http://dx.doi.org/10.2147/OTT.S109186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138047/
https://www.ncbi.nlm.nih.gov/pubmed/27942221
http://dx.doi.org/10.2147/OTT.S109186

Ejemplares similares